Skip to content
drillr.ai

BOLD

Boundless Bio, Inc.

NASDAQ · USHealthcareBiotechnology
$2.44-1.61%

Price as of Jul 20, 2026

BOLD news

Boundless Bio, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Halper Sadeh LLC is Investigating Whether DAN, ESI, NUVL, BOLD are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- Halpe

    Globe Newswire ·

  2. BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Element Solutions Inc. (NYSE – ESI), Boundless Bio Inc. (Nasdaq – BOLD), Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN)

    BALA CYNWYD, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. Element Solutions Inc. (NYSE – ESI) Under the terms of the Merger Agreement, Element Solutions will be acquired by Solstice Advanced Materials (Nasdaq - SOLS) i

    Globe Newswire ·

  3. Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, July 02, 2026 (GLOBE NEWSWIRE) -- Halpe

    Globe Newswire ·

  4. SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ACA, APGE, BOLD, and GBCS

    SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ACA, APGE, BOLD, and GBCS PR Newswire NEW YORK, July 2, 2026 NEW YORK, July 2, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4724546-2&h=3914342227&u=https%3A%2F%2Fprofiles.superlawyers.com%2Fnew-york%2Fnew-york%2Flawyer%2Fjuan-e-monteverde%2Fb861d99b-d20f-4376-92c4-2996390bacbc.html&a=Juan+Monteverde)  with Monteverde & Associates PC (https://edge.prn

    PR Newswire ·

  5. Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?

    Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsib

    PR Newswire ·

  6. $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)

    $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD) PR Newswire NEW YORK, June 23, 2026 NEW YORK, June 23, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4717871-1&h=2756234041&u=https%3A%2F%2Fprofiles.superlawyers.com%2Fnew-york%2Fnew-york%2Flawyer%2Fjuan-e-monteverde%2Fb861d99b-d20f-4376-92c4-2996390bacbc.html&a=Juan+Monteverde) with Monteverde & Associates PC (https://edge.

    PR Newswire ·

  7. BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders

    BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would

    Business Wire ·

  8. Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement

    Combined company to operate as Serapha Bio and to advance Serapha’s potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency Serapha’s lead program SERP-01 targets the SERPINA1 E342K (PiZZ) mutation, with proof-of-concept data demonstrating restoration of serum AAT to normal levels Concurrent $230 million private placement co-led by RTW Investments and RA Capital Management, with participation from syndicate of top healthcare investors and mutual funds Companies

    Globe Newswire ·

  9. Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting

    SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (https://www.globenewswire.com/Tracker?data=i1JBnVSEx37lNwOGYH3W3uSEIseSWd6xeAg5iNxrYvmElKFRo9yerc1RItKdY4Bsfq1xgBA-CSxoTF_THc4Ozkl79QOLRHeUS7miG2Vh8RI=) (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical data supporting its lead ecDNA-directed therapy (ecDTx), BBI

    Globe Newswire ·

  10. Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

    SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (https://www.globenewswire.com/Tracker?data=n4yJbUKc4_pKyF-WdNRLKEje_o_6SIGzL6qggQScTwB2kgR5OtFsfpUnAB60X44T9cuZoChSkA7_2pwU7wIBSk7ZJRx-G-4mjT84oHg7qPo=) (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced an upcoming poster presentation on their oral Kinesin degrader pr

    Globe Newswire ·